Needham & Company
-
Needham & Company Downgrades Progenics Pharmaceuticals (PGNX) to Hold; Concerns on Lack of Clarity with Relistor
-
Needham & Company Reiterates a 'Buy' on Progenics Pharmaceuticals (PGNX);
-
Needham & Company Maintains a 'Hold' on Progenics Pharmaceuticals (PGNX); In Waiting Mode
-
Notable Analyst Rating Changes 02/24: XCO, FPL, SLXP, EOG, ADSK Upgraded; STEC, APA, KND Downgraded
-
Morning Movers 2/24: BNE, VOCL, AHC, FFCO, SLXP Higher; STEC, HRB, TA, CENX Lower